Evidence map›Paper›PMID 38592150›Full record

ArticleJournal of clinical medicine2024

Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab.

Yun Beom Sang, Chaeryoung Lee, Seul-Gi Kim, Boyoung Lee, Beodeul Kang, Chan Kim, Hong Jae Chon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yun Beom SangMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13497, Republic of Korea.ORCID 0000-0002-1123-6313
Chaeryoung LeeDivision of Infectious Diseases, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13497, Republic of Korea.
Seul-Gi KimMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13497, Republic of Korea.ORCID 0000-0003-1641-4059
Boyoung LeeDivision of Allergy and Respiratory Diseases, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul 04401, Republic of Korea.
Beodeul KangMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13497, Republic of Korea.
Chan KimMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13497, Republic of Korea.ORCID 0000-0001-9780-6155
Hong Jae ChonMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13497, Republic of Korea.ORCID 0000-0002-6979-5812

Funding

National Research Foundation of Korea NRF-2023R1A2C2004339National Research Foundation of Korea NRF-2023R1A2C2006375
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atezolizumabbevacizumabcoronavirus disease 2019liver functionunresectable hepatocellular carcinoma

Identifiers

PMID38592150
PMCPMC10931976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.